ArQule, Isis shrug off sector's weaker trend
March 31, 2010 at 10:46 AM EDT
Shares of ArQule double in value as a Phase II clinical trial has shown the company’s ARQ 197 compound effective in helping slow the progression of lung cancer. Also trading higher are shares of Isis Pharmaceuticals, which has nailed down a drug-development collaboration pact with GlaxoSmithKline.
